Isatuximab in Lung Transplant Recipients

Antibody-mediated Rejection Clinical Trial

Official title:

A Pilot Study of Isatuximab in Addition to Standard Therapy for Desensitization or Antibody-mediated Rejection in Lung Transplant Recipients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05862766
• Other study ID #: 22-00992
• Status: Not yet recruiting
• Phase: Early Phase 1
• Start date: July 1, 2024
• Est. completion date: January 1, 2027

Study information

• Verified date: February 2024
• Source: NYU Langone Health
• Contact: Tyler Lewis, PharmD
• Phone: 866-838-5864
• Email: Tyler.lewis[@]nyulangone.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and feasibility of adding isatuximab to standard of care therapies in patients who will receive a lung transplant, but have significant antibodies against the donor (desensitization), or patients who have previously received a lung transplant and develop antibodies against the donor (antibody-mediated rejection, AMR). The study will compare the impact of isatuximab on the recurrence of antibodies after they have been removed from the blood by a process known as plasmapheresis that is standard of care for this condition. The use of isatuximab in lung transplant recipients is investigational, meaning it is not Food and Drug Administration (FDA) approved for use in lung transplant recipients. This study is a pilot study investigating the feasibility and safety of isatuximab in lung transplant patients. Isatuximab is an FDA approved drug indicated for the treatment of multiple myeloma. It may also be useful for transplant recipients with antibodies against the donor because it eliminates the cells that make antibodies.

Description:

This dual-arm pilot study will enroll approximately 6 patients undergoing lung transplantation at NYU Langone Health who are either receiving peri-transplant desensitization, or who are admitted for treatment of AMR. All patients will be treated with standard-of-care consisting of plasmaspheresis, IVIG, and rituximab. Additionally, the experimental agent, isatuximab, will be added to this treatment protocol. The patients will first receive 4 weekly doses of isatuximab, followed by 4 bi¬-weekly doses (total 8 doses given over 12 weeks). Patients will be followed with standard-of-care immunologic assessment consisting of weekly DSA assessment and flow cytometry crossmatch (only in the desensitization arm). Additionally, patients undergoing peri-transplant desensitization will have a bone marrow biopsy with pathologic examination and cell counts performed at the time of transplant and repeated at the 30-day bronchoscopy to assess for plasma cell elimination.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 6
• Est. completion date: January 1, 2027
• Est. primary completion date: January 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

Cohort A (Desensitization) Inclusion Criteria:

• Age = 18 years
• Listed and will receive a lung transplant or multi-organ transplant involving a lung at NYU Langone Health that is deemed to require peri-transplant desensitization
• Able and willing to provide informed consent
• Pre-transplant DSA > 5,000 MFI in undiluted serum (measured as individual DSA MFI or as sum of multiple DSAs >1000 MFI in the undiluted serum)

Cohort B (AMR) Inclusion Criteria:

• Age = 18 years
• Received a lung transplant or multi-organ transplant involving a lung at NYU Langone Health
• Able and willing to provide informed consent
• Allograft dysfunction in the setting of at least one of the following criteria:
• Histopathology suggestive of AMR
• Lung biopsy demonstrating C4d deposition
• Positive DSA > 2,000 MFI (as individual DSA MFI)

Exclusion Criteria:

• Prior or current treatment with rituximab within 6 months of isatuximab administration
• Prior or current treatment with tocilizumab within 6 months of isatuximab administration
• Contraindication to isatuximab due to intolerance or hypersensitivity
• Pregnant or breastfeeding women
• Known malignancy
• Active infection without adequate treatment or source control
• Known hepatitis B viral infection
• Known HIV infection

Related Conditions & MeSH terms

• Allosensitization
• Antibody-mediated Rejection

Intervention

Drug:
• Isatuximab
The dose will consist of isatuximab 10 mg/kg actual body weight given weekly for the first 4 weeks, followed by 10 mg/kg biweekly for an additional 4 doses. Isatuximab is a clear, colorless to slightly yellow solution. It is supplied as 100 mg/5 mL or 500 mg/25 mL single-dose vials.

Procedure:
• bone marrow biopsy
Bone marrow biopsy at the time of lung transplantation and at approximately 1 month following completion of therapy. Initial bone marrow biopsy to be performed during the lung transplant operation and to be collected from the sternum by the operating surgeon. Follow-up bone marrow biopsy to be completed by credentialed hematologist during a regularly scheduled follow-up bronchoscopy with standard procedural anesthesia sedation.

Locations

Country	Name	City	State
United States	NYU Langone Health	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical Resolution, as measured by the number of participants with less than 1 episode of Antibody-mediated rejection (AMR)	Participants undergoing desensitization will have stable supplemental oxygen requirement or no supplemental oxygen requirement	Day 0 (Visit 1)
Primary	Clinical Resolution, as measured by the number of participants with less than 1 episode of Antibody-mediated rejection (AMR)	Participants undergoing desensitization will have stable supplemental oxygen requirement or no supplemental oxygen requirement	Day 28 (Visit 5)
Primary	Clinical Resolution, as measured by the number of participants with no presence of Donor-specific antibody (DSA)	Participants undergoing desensitization will have no presence of Donor-specific-antibody	Day 0 (Visit 1)
Primary	Clinical Resolution, as measured by the number of participants with no presence of Donor-specific antibody (DSA)	Participants undergoing desensitization will have no presence of Donor-specific-antibody	Day 28 (Visit 5)
Primary	Clinical Resolution, as measured by the number of participants with reduction of DSA titer	Participants undergoing desensitization will have no presence of Donor-specific-antibody measured by DSA titer or by C1q assay.	Day 0 (Visit 1)
Primary	Clinical Resolution, as measured by the number of participants with reduction of DSA titer	Participants undergoing desensitization will have no presence of Donor-specific-antibody measured by DSA titer or by C1q assay.	Day 28 (Visit 5)
Secondary	Change in effects of pre-treatment Donor-Specific-Antibodies (DSAs ) with <2000 Mean fluorescent intensity (MFI) at 1:16 dilution	Percent Mean fluorescent intensity (MFI) change in undiluted serum	Day 0 (Visit 1), Day 14 (Visit 3), Day 28 (Visit 5), Day 56 (Visit 7), Day 84 (Visit 9)
Secondary	Change in effects of pre-treatment Donor-Specific-Antibodies (DSAs ) with 2001-7999 Mean fluorescent intensity (MFI) at 1:16 dilution	Percent moderate titer DSA with <1000 Mean fluorescent intensity (MFI) at 1:16 dilution	Day 0 (Visit 1), Day 14 (Visit 3), Day 28 (Visit 5), Day 56 (Visit 7), Day 84 (Visit 9)
Secondary	Change in effects of pre-treatment Donor-Specific-Antibodies (DSAs ) = 8000 Mean fluorescent intensity (MFI) at 1:16 dilution	Percent Mean fluorescent intensity (MFI) reduction of high titer DSAs at 1:16 dilution	Day 0 (Visit 1), Day 14 (Visit 3), Day 28 (Visit 5), Day 56 (Visit 7), Day 84 (Visit 9)